These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9118509)

  • 1. Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state.
    Ferro D; Pittoni V; Quintarelli C; Basili S; Saliola M; Caroselli C; Valesini G; Violi F
    Circulation; 1997 Mar; 95(6):1425-32. PubMed ID: 9118509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus.
    Ferro D; Basili S; Roccaforte S; Di Franco M; Cipollone F; Ciabattoni G; Davì G
    Arthritis Rheum; 1999 Dec; 42(12):2689-97. PubMed ID: 10616019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus.
    Martini F; Farsi A; Gori AM; Boddi M; Fedi S; Domeneghetti MP; Passaleva A; Prisco D; Abbate R
    Lupus; 1996 Jun; 5(3):206-11. PubMed ID: 8803891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiphospholipid antibodies in pediatric systemic lupus erythematosus.
    Seaman DE; Londino AV; Kwoh CK; Medsger TA; Manzi S
    Pediatrics; 1995 Dec; 96(6):1040-5. PubMed ID: 7491218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of autoimmunity and inflammation on endothelial function and thrombosis in systemic lupus erythematosus patients.
    Bugała K; Mazurek A; Gryga K; Komar M; Kopeć G; Musiał J; Podolec P; Perricone C; Płazak W
    Clin Rheumatol; 2018 Aug; 37(8):2087-2093. PubMed ID: 29675623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies.
    Martinuzzo ME; Forastiero RR; Kordich L; Carreras LO
    Br J Haematol; 2001 Sep; 114(4):845-51. PubMed ID: 11564073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
    Horbach DA; van Oort E; Donders RC; Derksen RH; de Groot PG
    Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-phospholipid antibodies contribute to arteriosclerosis in patients with systemic lupus erythematosus through induction of tissue factor expression and cytokine production from peripheral blood mononuclear cells.
    Motoki Y; Nojima J; Yanagihara M; Tsuneoka H; Matsui T; Yamamoto M; Ichihara K
    Thromb Res; 2012 Oct; 130(4):667-73. PubMed ID: 22196362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
    İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
    Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated levels of soluble CD40 ligand are associated with antiphospholipid antibodies in patients with systemic lupus erythematosus.
    Kim KJ; Baek IW; Yoon CH; Kim WU; Cho CS
    Clin Exp Rheumatol; 2017; 35(5):823-830. PubMed ID: 28421990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
    Cabiedes J; Cabral AR; Alarcón-Segovia D
    J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus.
    Tomás JF; Alberca I; Tabernero MD; Cordero M; Del Pino-Montes J; Vicente V
    J Rheumatol; 1998 Jan; 25(1):57-62. PubMed ID: 9458203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus.
    Sabet A; Sibbitt WL; Stidley CA; Danska J; Brooks WM
    Stroke; 1998 Nov; 29(11):2254-60. PubMed ID: 9804631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiac abnormalities in patients with systemic lupus erythematosus: the role of antiphospholipid antibodies].
    Monti M; Borgognoni F; Pastacci L; Vincentelli GM
    G Ital Cardiol (Rome); 2016 Dec; 17(12):1001-1007. PubMed ID: 28151504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome.
    Dignat-George F; Camoin-Jau L; Sabatier F; Arnoux D; Anfosso F; Bardin N; Veit V; Combes V; Gentile S; Moal V; Sanmarco M; Sampol J
    Thromb Haemost; 2004 Apr; 91(4):667-73. PubMed ID: 15045126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein s.
    Reverter JC; Tàssies D; Font J; Monteagudo J; Escolar G; Ingelmo M; Ordinas A
    Arterioscler Thromb Vasc Biol; 1996 Nov; 16(11):1319-26. PubMed ID: 8911269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lupus anticoagulant and history of thrombosis are not associated with persistent endothelial cell activation in systemic lupus erythematosus.
    Frijns CJ; Derksen RH; De Groot PG; Algra A; Fijnheer R
    Clin Exp Immunol; 2001 Jul; 125(1):149-54. PubMed ID: 11472438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Ro and Concomitant Anti-La Autoantibodies Strongly Associated With Anti-oxLDL or Anti-Phospholipid Antibody in Systemic Lupus Erythematosus.
    Kurien BT; Fesmire J; Anderson CJ; Scofield RH
    J Clin Rheumatol; 2016 Dec; 22(8):418-425. PubMed ID: 27870764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
    Zuily S; Regnault V; Guillemin F; Kaminsky P; Rat AC; Lecompte T; Wahl D
    Thromb Res; 2013 Jul; 132(1):e1-7. PubMed ID: 23676348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.